

13 February 2024

## Usage of Intra-Vitreous Injections or Implants

1. How many of the following intra-vitreous injections/implants has your Trust administered in the four-month period from September to December 2023:

• Aflibercept	4875
• Bevacizumab – Avastin	10
• Bevacizumab – Biosimilar	-
• Brolucizumab	-
• Dexamethasone	64
• Faricimab	241
• Fluocinolone acetonide	0
• Ranibizumab - Lucentis (pre-filled syringes)	904
• Ranibizumab - Lucentis (vials)	-
• Ranibizumab – Ongavia	-

2. Please provide the number of injections/implants by eye condition for the four-month period from September to December 2023:

Treatment	Eye Conditions		
	Wet Age-Related Macular Degeneration (wAMD)	Diabetic Macular Oedema (DMO)	Retinal Vein Occlusion (RVO)
Aflibercept	3606	591	678
Bevacizumab	6	4	0
Dexamethasone	19	24	21
Faricimab	125	116	0
Ranibizumab - Lucentis	717	87	100
Ranibizumab - Ongavia			